Clinical Applications of Cholinergic Receptor Blockers
Anticholinergic Drugs -- Anesthesia Applications/Issues
Overview:
Preoperative medication
Management of reflex bradycardia
Use in antagonism of nondepolarizing neuromuscular-blocking agents
Common Applications-- anesthesia related (anticholinergic agents)
Preoperative medications
Management of reflex bradycardia
Combinations with anticholinesterase agents during pharmacological antagonism of nondepolarizing neuromuscular-blocking agents
Other Applications of anticholinergic drugs:
Bronchodilation (e.g.,asthma)
Biliary/ureteral smooth muscle relaxation
To cause mydriasis/cycloplegia
Inhibition of parietal cells acid secretion
Prevention of motion sickness (nausea)
Component in cold remedies
Central Nervous System Effects of Antimuscarinic Agents
In normal doses, atropine produces little CNS effect.
In toxic doses, CNS excitation results in restlessness, hallucinations, and disorientation.
At very high doses, atropine can lead to CNS depression which causes circulatory and respiratory collapse.
By contrast, scopolamine at normal therapeutic doses causes CNS depression, including drowsiness, fatigue and amnesia.
Scopolamine also may produce euphoria, a basis for some abuse potential.
Scopolamine may exhibit more CNS activity than atropine because scopolamine crosses the blood brain barrier more readily.
Antimuscarinics are used clinically as preanesthetic medication to reduce vagal effects secondary to visceral manipulation during surgery.
Antimuscarinics with L-DOPA are used in Parkinson's disease.
Extrapyramidal effects induced by some antipsychotic drugs may be treated with antimuscarinic agents.
Scopolamine (transdermal) is effective in preventing motion sickness.
Atropine is also an effective antidote to excessive cholinergic stimulation following organophosphate intoxication.
By blocking muscarinic receptors, the consequences of cholinesterase inhibition is attentuated.
Atropine may be used in conjunction with 2-PAM which may reactivate phosphorylated, inhibited acetylcholinesterase by nucleophilic displacement.
Taylor, P. Agents Acting at the Neuromuscular Junction and Autonomic Ganglia In, Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) The McGraw-Hill Companies, Inc.,1996, pp.193-195. Adapted from Table 9-3.